Home » Stocks » LMNX

Luminex Corporation (LMNX)

Stock Price: $24.14 USD -0.45 (-1.83%)
Updated December 3, 2:10 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 1.12B
Revenue (ttm) 396.50M
Net Income (ttm) 18.04M
Shares Out 45.46M
EPS (ttm) 0.40
PE Ratio 60.35
Forward PE n/a
Dividend $0.36
Dividend Yield 1.49%

Stock Quote

Trading Day December 3
Last Price $24.14
Previous Close $24.59
Change ($) -0.45
Change (%) -1.83%
Day's Open 24.60
Day's Range 23.78 - 24.65
Day's Volume 218,564
52-Week Range 20.14 - 40.35

More Stats

Market Cap 1.12B
Enterprise Value 1.03B
Earnings Date (est) n/a
Ex-Dividend Date Sep 23, 2020
Shares Outstanding 45.46M
Float n/a
EPS (basic) 0.39
EPS (diluted) 0.40
FCF / Share 0.65
Dividend $0.36
Dividend Yield 1.49%
Earnings Yield 1.66%
FCF Yield 2.63%
Payout Ratio 92.30%
Shares Short 4.00M
Short Ratio 7.23
Short % of Float n/a
Beta 0.62
PE Ratio 60.35
Forward PE n/a
P/FCF Ratio 37.99
PS Ratio 2.83
PB Ratio 2.09
Revenue 396.50M
Operating Income 34.93M
Net Income 18.04M
Free Cash Flow 29.57M
Net Cash 93.46M
Net Cash / Share 2.01
Gross Margin 46.36%
Operating Margin 8.81%
Profit Margin 4.60%
FCF Margin 7.46%
ROA 3.34%
ROE 3.75%
ROIC 10.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$36.00*
(49.13% upside)
Low
22.0
Current: $24.14
High
48.0
Target: 36.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue335316307271238227213203184142
Revenue Growth5.96%3.02%13.28%13.85%4.73%6.35%5.35%9.9%30.22%-
Gross Profit18319519918016916014414312596.38
Operating Income-12.0827.8537.1520.9932.0628.144.7722.7223.8411.25
Net Income-3.7718.2028.8913.8136.8639.047.1012.4114.475.23
Shares Outstanding44.1543.7343.1742.5842.0941.5640.8040.9341.2641.03
Earnings Per Share-0.090.410.670.320.860.930.170.300.340.12
EPS Growth--38.81%109.38%-62.79%-7.53%447.06%-43.33%-11.76%183.33%-
Dividend Per Share0.300.240.24-------
Dividend Growth25%0%--------
Operating Cash Flow13.5450.9057.4349.6857.3851.3426.9024.2838.2924.18
Capital Expenditures-16.25-21.29-14.64-13.13-18.71-17.08-18.09-9.77-9.55-11.10
Free Cash Flow-2.7129.6142.8036.5538.6834.278.8114.5228.7413.07
Cash & Equivalents59.1776.4412793.4514191.6972.4456.40102119
Total Debt17.18-----1.662.843.574.20
Net Cash / Debt41.9976.4412793.4514191.6970.7853.5698.29115
Assets544525491451403358306297283266
Liabilities78.8757.5252.6147.0434.0237.5336.4337.5131.7930.95
Book Value465468438404369320270260251235
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Luminex Corporation
Country United States
Employees 1,257
CEO Nachum Shamir

Stock Information

Ticker Symbol LMNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: LMNX
IPO Date March 30, 2000

Description

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; FlowSight Imaging Flow cytometer; ImageStream System; CellStream Flow Cytometer; Guava easyCyte line; and Muse Cell Analyzer. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.